EyePoint Pharmaceuticals Inc (PSDV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:EyePoint Pharmaceuticals Inc (PSDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12370
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

EyePoint Pharmaceuticals Inc (PSDV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
pSivida and Nicox Enter into Agreement 13
pSivida Enters into Agreement with Major Global Pharmaceutical Company 14
Licensing Agreements 15
Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 15
Equity Offering 16
EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 16
EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 17
EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 18
EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 19
EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 20
EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 21
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 22
pSivida Raises USD17.8 Million in Public Offering of Shares 23
pSivida Raises USD7 Million in Private Placement of Shares 25
pSivida Announces Private Placement Of Shares For US$19 Million 26
pSivida Completes Public Offering Of Shares For US$10.8 Million 27
pSivida Completes Private Placement Of Units For US$5.4 Million 28
Acquisition 29
pSivida Acquires Icon Bioscience 29
EyePoint Pharmaceuticals Inc – Key Competitors 31
EyePoint Pharmaceuticals Inc – Key Employees 32
EyePoint Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 06, 2018: EyePoint Pharmaceuticals reports fiscal first quarter 2019 financial results and highlights recent clinical and operational developments 34
Sep 12, 2018: EyePoint Pharmaceuticals reports fiscal 2018 fourth quarter & full year financial results and highlights recent progress 36
May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results 39
Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 41
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 42
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 43
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 44
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 45
May 04, 2017: pSivida Q3 net loss increases 46
Feb 07, 2017: pSivida Reports Fiscal 2017 Second Quarter and First Half Results 47
Corporate Communications 49
Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary 49
Oct 30, 2018: EyePoint Pharmaceuticals appoints John Landis, Ph.D., M.S., to Board of Directors 50
Sep 10, 2018: EyePoint Pharmaceuticals names Goran Ando as Next Chairman of Board of Directors 51
Aug 15, 2018: Eyepoint Pharmaceuticals appoints John Weet, Ph.D., as SVP, regulatory affairs & quality 52
Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director 53
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
pSivida and Nicox Enter into Agreement 13
pSivida Enters into Agreement with Major Global Pharmaceutical Company 14
Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 15
EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 16
EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 17
EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 18
EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 19
EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 20
EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 21
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 22
pSivida Raises USD17.8 Million in Public Offering of Shares 23
pSivida Raises USD7 Million in Private Placement of Shares 25
pSivida Announces Private Placement Of Shares For US$19 Million 26
pSivida Completes Public Offering Of Shares For US$10.8 Million 27
pSivida Completes Private Placement Of Units For US$5.4 Million 28
pSivida Acquires Icon Bioscience 29
EyePoint Pharmaceuticals Inc, Key Competitors 31
EyePoint Pharmaceuticals Inc, Key Employees 32
EyePoint Pharmaceuticals Inc, Subsidiaries 33

List of Figures
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[EyePoint Pharmaceuticals Inc (PSDV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Korea Development Bank:企業の戦略・SWOT・財務情報
    Korea Development Bank - Strategy, SWOT and Corporate Finance Report Summary Korea Development Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • MicroPort Scientific Corp (853):企業の製品パイプライン分析2018
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company which develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, e …
  • Healthsense Inc-医療機器分野:企業M&A・提携分析
    Summary Healthsense Inc (Healthsense), a subsidiary of GreatCall Inc is a medical device company that provides remote monitoring services. The company offers technology-enabled care solutions, aging technology services, for the entire senior care continuum. Its products include eNeighbor remote moni …
  • Dayton Superior Corp:企業の戦略的SWOT分析
    Dayton Superior Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • RP Management LLC-製薬・医療分野:企業M&A・提携分析
    Summary RP Management LLC (RP Management) is a life sciences financing company which offers biopharmaceutical products. Its products portfolio includes rituxan, atripla, thalomid, myozyme, lexiscan, januvia, onglyza, lyrica, prezista, letairis, rotateq, cubicin, savella, neupogen, and others. The co …
  • Accrol Group Holdings PLC (ACRL):企業の財務・戦略的SWOT分析
    Accrol Group Holdings PLC (ACRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Vectura Group plc:企業の戦略・SWOT・財務分析
    Vectura Group plc - Strategy, SWOT and Corporate Finance Report Summary Vectura Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Biosceptre International Ltd-医療機器分野:企業M&A・提携分析
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Biosceptre’s diagnostic products are …
  • Air Water Inc (4088):企業の財務・戦略的SWOT分析
    Air Water Inc (4088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Industrial and Commercial Bank of China Ltd:企業のM&A・事業提携・投資動向
    Industrial and Commercial Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial and Commercial Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Kwantas Corporation Berhad:企業の戦略・SWOT・財務分析
    Kwantas Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Kwantas Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析
    Summary BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid l …
  • Aker Solutions ASA (AKSO)-石油・ガス分野:企業M&A・提携分析
    Summary Aker Solutions ASA (Aker Solutions) is a global provider of engineering, design, production systems and services to the oil and gas industry. The company offers subsea production equipment and offshore field design, ranging from concept studies and front-end engineering to subsea production …
  • Charles River Laboratories International, Inc.:企業の戦略・SWOT・財務情報
    Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • SAES Getters S.p.A. (SG):企業の財務・戦略的SWOT分析
    SAES Getters S.p.A. (SG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Chembond Chemicals Ltd (530871):企業の財務・戦略的SWOT分析
    Chembond Chemicals Ltd (530871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Mitsui E&S Holdings Co., Ltd. (7003):電力:M&Aディール及び事業提携情報
    Summary Mitsui E&S Holdings Co., Ltd. (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising environment recycling, construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, pla …
  • The Second Cup Ltd.:企業の戦略・SWOT・財務分析
    The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • FANUC CORPORATION:企業の戦略・SWOT・財務分析
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆